Antidepressant-like effects of quercetin in diabetic rats are independent of hypothalamic-pituitary-adrenal axis

Acta Neuropsychiatrica

Volumn 28, Issue 1, 2015, Pages 23-30

  Demir, Enver Ahmet ^a   Gergerlioglu, Hasan Serdar ^b   Oz, Mehmet ^c  

^a MUSTAFA KEMAL UNIVERSITY   (Turkey)

^b SELCUK UNIVERSITY   (Turkey)

^c MEVLANA UNIVERSITY   (Turkey)

Author keywords

adrenocorticotropic hormone; corticosterone; depression; experimental diabetes mellitus; quercetin

Indexed keywords

CORTICOSTERONE; CORTICOTROPIN; GLUCOSE; QUERCETIN; ANTIDEPRESSANT AGENT; ANTINEOPLASTIC ANTIBIOTIC; ANTIOXIDANT;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; CORTICOTROPIN BLOOD LEVEL; DRUG DOSE COMPARISON; FORCED SWIM TEST; GLYCEMIC CONTROL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MALE; MORNING DOSAGE; NONHUMAN; RAT; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; WEIGHT REDUCTION; ANIMAL; BLOOD; CHEMICALLY INDUCED; DEPRESSION; DIABETES MELLITUS, EXPERIMENTAL; DRUG EFFECTS; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; INTRAPERITONEAL DRUG ADMINISTRATION; MOTOR ACTIVITY; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGY; SWIMMING; WISTAR RAT;

ADRENOCORTICOTROPIC HORMONE; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIDEPRESSIVE AGENTS; ANTIOXIDANTS; CORTICOSTERONE; DEPRESSION; DIABETES MELLITUS, EXPERIMENTAL; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; INJECTIONS, INTRAPERITONEAL; MALE; MOTOR ACTIVITY; PITUITARY-ADRENAL SYSTEM; QUERCETIN; RATS; RATS, WISTAR; SWIMMING;

EID: 84952873765     PISSN: 09242708     EISSN: 16015215     Source Type: Journal    
DOI: 10.1017/neu.2015.45     Document Type: Article

References (62)

1. International Diabetes Federation. IDF Diabetes Atlas: International Diabetes Federation; 2013. Available at http://www.idf.org/diabetesatlas. Accessed February 3, 2013.
2. TRIPATHI BK, SRIVASTAVA AK. Diabetes mellitus: complications and therapeutics. Med Sci Monit 2006;12: RA130-RA147.
3. RUBIN RR, PEYROT M. Was Willis right? Thoughts on the interaction of depression and diabetes. Diabetes Metab Res Rev 2002;18:173-175.
4. GOIS C, AKISKAL H, AKISKAL K, FIGUEIRA ML. Depressive temperament, distress, psychological adjustment and depressive symptoms in type 2 diabetes. J Affect Disord 2012;143:1-4.
5. World Health Organization. Depression Fact Sheet; 2012. Available at http://www.who.int/mediacentre/factsheets/fs369/en/. Accessed March 10, 2014.
6. FERRARI AJ, CHARLSON FJ, NORMAN RE et al. Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. PLoS Med 2013;10:e1001547.
7. REDDY MS. Depression: the disorder and the burden. Indian J Psychol Med 2010;32:1-2.
8. MURRAY CJ, VOS T, LOZANO R et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2197-2223.
9. PATKI G, SOLANKI N, ATROOZ F, ALLAM F, SALIM S. Depression, anxiety-like behavior and memory impairment are associated with increased oxidative stress and inflammation in a rat model of social stress. Brain Res 2013;1539:73-86.
10. ZATALIA SR, SANUSI H. The role of antioxidants in the pathophysiology, complications, and management of diabetes mellitus. Acta Med Indones 2013;45:141-147.
11. SIWEK M, SOWA-KUCMA M, DUDEK D et al. Oxidative stress markers in affective disorders. Pharmacol Rep 2013;65: 1558-1571.
12. KHANSARI N, SHAKIBA Y, MAHMOUDI M. Chronic inflammation and oxidative stress as a major cause of agerelated diseases and cancer. IAD 2009;3:73-80.
13. LEONARD B, MAES M. Mechanistic explanations how cellmediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev 2012;36: 764-785.
14. ASCHBACHER K, O'DONOVAN A, WOLKOWITZ OM, DHABHAR FS, SU Y, EPEL E. Good stress, bad stress and oxidative stress: insights from anticipatory cortisol reactivity. Psychoneuroendocrinology 2013;38:1698-1708.
15. TERLECKY SR, TERLECKY LJ, GIORDANO CR. Peroxisomes, oxidative stress, and inflammation. World J Biol Chem 2012;3:93-97.
16. SPIERS JG, CHEN HC, SERNIA C, LAVIDIS NA. Activation of the hypothalamic-pituitary-adrenal stress axis induces cellular oxidative stress. Front Neurosci 2014;8:456.
17. CAVANAGH J, MATHIAS C. Inflammation and its relevance to psychiatry. Adv Psychiatr Treat 2008;14:248-255.
18. RUSTAD JK, MUSSELMAN DL, NEMEROFF CB. The relationship of depression and diabetes: pathophysiological and treatment implications. Psychoneuroendocrinology 2011;36:1276-1286.
19. KATON W. Depression and diabetes: unhealthy bedfellows. Depress Anxiety 2010;27:323-326.
20. MÜLLER N. Immunology of major depression. Neuroimmunomodulation 2014;21:123-130.
21. ANDERSON RJ, FREEDLAND KE, CLOUSE RE, LUSTMAN PJ. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care 2001;24:1069-1078.
22. KUMAR S, PANDEY AK. Chemistry and biological activities of flavonoids: an overview. Scientific World Journal 2013;2013: 1-16.
23. LIU F, AGRAWAL SG, MOVASAGHI Z et al. Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib. Blood 2008;112:3835-3846.
24. KINOSHITA T, LEPP Z, KAWAI Y, TERAO J, CHUMAN H. An integrated database of flavonoids. Biofactors 2006;26: 179-188.
25. KNEKT P, KUMPULAINEN J, JARVINEN R et al. Flavonoid intake and risk of chronic diseases. Am J Clin Nutr 2002; 76:560-568.
26. MORAND C, CRESPY V, MANACH C, BESSON C, DEMIGNE C, REMESY C. Plasma metabolites of quercetin and their antioxidant properties. Am J Physiol 1998;275:R212-R219.
27. KAHRAMAN A, ÇAKAR H, KÖKEN T. The protective effect of quercetin on long-term alcohol consumption-induced oxidative stress. Mol Biol Rep 2012;39:2789-2794.
28. BOOTS AW, HAENEN GR, BAST A. Health effects of quercetin: from antioxidant to nutraceutical. Eur J Pharmacol 2008;585: 325-337.
29. KOBORI M, MASUMOTO S, AKIMOTO Y, TAKAHASHI Y. Dietary quercetin alleviates diabetic symptoms and reduces streptozotocin-induced disturbance of hepatic gene expression in mice. Mol Nutr Food Res 2009;53:859-868.
30. COSKUN O, KANTER M, KORKMAZ A, OTER S. Quercetin, a flavonoid antioxidant, prevents and protects streptozotocininduced oxidative stress and beta-cell damage in rat pancreas. Pharmacol Res 2005;51:117-123.
31. JEONG S, KANG M, CHOI H, KIM J, KIM J. Quercetin ameliorates hyperglycemia and dyslipidemia and improves antioxidant status in type 2 diabetic db/db mice. Nutr Res Pract 2012;6:201-207.
32. KIM J, KANG M, CHOI H, JEONG S, LEE Y, KIM J. Quercetin attenuates fasting and postprandial hyperglycemia in animal models of diabetes mellitus. Nutr Res Pract 2011;5:107-111.
33. MOHAMMADI HS, GOUDARZI I, LASHKARBOLOUKI T, ABRARI K, ELAHDADI SALMANI M. Chronic administration of quercetin prevent spatial learning and memory deficits provoked by chronic stress in rats. Behav Brain Res 2014;270: 196-205.
34. KAWABATA K, KAWAI Y, TERAO J. Suppressive effect of quercetin on acute stress-induced hypothalamic-pituitaryadrenal axis response in Wistar rats. J Nutr Biochem 2010;21:374-380.
35. HALEAGRAHARA N, RADHAKRISHNAN A, LEE N, KUMAR P. Flavonoid quercetin protects against swimming stressinduced changes in oxidative biomarkers in the hypothalamus of rats. Eur J Pharmacol 2009;621:46-52.
36. SABATÉ E. Adherence to Long-Term Therapies: Evidence for Action. Geneva: World Health Organization, 2003.
37. TAMBURRINO MB, NAGEL RW, CHAHAL MK, LYNCH DJ. Antidepressant medication adherence. Prim Care Companion J Clin Psychiatry 2009;11:205-211.
38. BOGDANOVA OV, KANEKAR S, D'ANCI KE, RENSHAW PF. Factors influencing behavior in the forced swim test. Physiol Behav 2013;118:227-239.
39. CALETTI G, OLGUINS DB, PEDROLLO EF, BARROS HM, HELENA MT, GOMEZ R. Antidepressant effect of taurine in diabetic rats. Amino Acids 2012;43:1525-1533.
40. YANKELEVITCH-YAHAV R, FRANKO M, HULY A, DORON R. The forced swim test as a model of depressive-like behavior. J Vis Exp 2015;2.
41. MCLAUGHLIN JP, LAND BB, LI S, PINTAR JE, CHAVKIN C. Prior activation of kappa opioid receptors by U50,488 mimics repeated forced swim stress to potentiate cocaine place preference conditioning. Neuropsychopharmacology 2006; 31:787-794.
42. MACIEL RM, COSTA MM, MARTINS DB et al. Antioxidant and anti-inflammatory effects of quercetin in functional and morphological alterations in streptozotocin-induced diabetic rats. Res Vet Sci 2013;95:389-397.
43. MAHMOUD MF, HASSAN NA, EL BASSOSSY HM, FAHMY A. Quercetin protects against diabetes-induced exaggerated vasoconstriction in rats: effect on low grade inflammation. PLoS One 2013;8:e63784.
44. ELBE H, VARDI N, ESREFOGLU M, ATES B, YOLOGLU S, TASKAPAN C. Amelioration of streptozotocin-induced diabetic nephropathy by melatonin, quercetin, and resveratrol in rats. Hum Exp Toxicol 2014;34:100-113.
45. ORŠOLIĆ N, GAJSKI G, GARAJ-VRHOVAC V, DIKIĆ D, PRSKALO ZŠ, SIROVINA D. DNA-protective effects of quercetin or naringenin in alloxan-induced diabetic mice. Eur J Pharmacol 2011;656:110-118.
46. MAHESH T, MENON VP. Quercetin allievates oxidative stress in streptozotocin-induced diabetic rats. Phytother Res 2004;18:123-127.
47. CHOUGALA MB, BHASKAR JJ, RAJAN MGR, SALIMATH PV. Effect of curcumin and quercetin on lysosomal enzyme activities in streptozotocin-induced diabetic rats. Clin Nutr 2012;31:749-755.
48. ZSILA F, BIKADI Z, SIMONYI M. Probing the binding of the flavonoid, quercetin to human serum albumin by circular dichroism, electronic absorption spectroscopy and molecular modelling methods. Biochem Pharmacol 2003; 65:447-456.
49. SILBERBERG M, MORAND C, MANACH C, SCALBERT A, REMESY C. Co-administration of quercetin and catechin in rats alters their absorption but not their metabolism. Life Sci 2005;77:3156-3167.
50. LAN K, HE J, TIAN Y, TAN F, JIANG X, WANG L et al. Intraherb pharmacokinetics interaction between quercetin and isorhamentin. Acta Pharmacol Sin 2008;29:1376-1382.
51. KIM HG, LEE JH, LEE SJ et al. The increased cellular uptake and biliary excretion of curcumin by quercetin: a possible role of albumin binding interaction. Drug Metab Dispos 2012;40:1452-1455.
52. WANG Y, ZHAO Y, YANG F, YUAN Y, WANG H, XIAO J. Influences of glucose on the dietary hydroxyflavonoid-plasma protein interaction. J Agric Food Chem 2012;60:12116-12121.
53. CRYAN JF, MARKOU A, LUCKI I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci 2002;23:238-245.
54. CASTAGNÉ V, PORSOLT RD, MOSER P. Use of latency to immobility improves detection of antidepressant-like activity in the behavioral despair test in the mouse. Eur J Pharmacol 2009;616:128-133.
55. MERZOUG S, TOUMI ML, TAHRAOUI A. Quercetin mitigates adriamycin-induced anxiety- and depression-like behaviors, immune dysfunction, and brain oxidative stress in rats. Naunyn Schmiedebergs Arch Pharmacol 2014;387:921-933.
56. BHUTADA P, MUNDHADA Y, BANSOD K et al. Reversal by quercetin of corticotrophin releasing factor induced anxiety- and depression-like effect in mice. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:955-960.
57. ANJANEYULU M, CHOPRA K, KAUR I. Antidepressant activity of quercetin, a bioflavonoid, in streptozotocin-induced diabetic mice. J Med Food 2003;6:391-395.
58. CHAN O, INOUYE K, RIDDELL MC, VRANIC M, MATTHEWS SG. Diabetes and the hypothalamo-pituitary-adrenal (HPA) axis. Minerva Endocrinol 2003;28:87-102.
59. MARIC NP, ADZIC M. Pharmacological modulation of HPA axis in depression - new avenues for potential therapeutic benefits. Psychiatr Danub 2013;25:299-305.
60. LEIHERER A, MÜNDLEIN A, DREXEL H. Phytochemicals and their impact on adipose tissue inflammation and diabetes. Vascul Pharmacol 2013;58:3-20.
61. DEMIR EA, OZ M, ALP MI, GERGERLIOGLU HS. Levels of IL-6 and TNF-a in diabetic rats: effect of quercetin. ISJMS 2015;1:27-31.
62. GERGERLIOGLU HS, GOKBEL H, OKUDAN N, GERGERLIOGLU N, DEMIR EA. Quercetin and caffeic acid phenethyl ester (CAPE) attenuate acute exercise-induced oxidative stress. Prog Nutr 2015;17:41-49.